Sangamo Therapeutics, Inc.
SGMOQ Healthcare Biotechnology
Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024. In the quarter to March 2026, revenue fell 77.6%, EPS grew 42.9% and free cash flow grew 26.2%, each against the same quarter a year earlier.
Follow SGMOQ
Sangamo Therapeutics, Inc. (SGMOQ) EV/Sales
As of 16 October 2026, Sangamo Therapeutics, Inc. (SGMOQ) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from −0.3× (November 2023) to 50.3× (March 2018); the current reading is higher than 10% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | (5.05%) |
| FY2024 | 3.3× | 1,215.81% |
| FY2023 | 0.3× | (88.06%) |
| FY2022 | 2.1× | (68.26%) |
| FY2021 | 6.6× | (47.13%) |
| FY2020 | 12.6× | 113.21% |
| FY2019 | 5.9× | (32.79%) |
| FY2018 | 8.8× | (72.17%) |
| FY2017 | 31.5× | 662.21% |
| FY2016 | 4.1× | (61.81%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 2.8× | (10.31%) |
| Dec 2025 | 3.1× | (48.55%) |
| Sep 2025 | 6.1× | 290.02% |
| Jun 2025 | 1.6× | (32.41%) |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| VERU Veru Inc. compare | 1.2× |
| SGMOQ Sangamo Therapeutics, Inc. | 1.2× |
| CELU Celularity, Inc. compare | 4.1× |
| SER Serina Therapeutics, Inc. compare | 66.0× |
| GRCE Grace Therapeutics, Inc. compare | 109× |
| TIL Instil Bio, Inc. compare | 401× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)